These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28748718)

  • 21. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL; Zhang W; McCollum M
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.
    Hsu CY; Su YW; Chen YT; Tsai SH; Chang CC; Li SY; Huang PH; Chen JW; Lin SJ
    Cardiovasc Diabetol; 2016 Sep; 15(1):125. PubMed ID: 27585542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
    Howlett H; Porte F; Allavoine T; Kuhn T; Nicholson G
    Curr Med Res Opin; 2003; 19(3):218-25. PubMed ID: 12803736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes mellitus and the risk of cancer.
    Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
    Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.
    Opie LH
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):331-4. PubMed ID: 24825435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents.
    Pollex EK; Hutson JR
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):325-39. PubMed ID: 21247371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diabetes mellitus, antidiabetics and bone].
    Svacina S
    Cas Lek Cesk; 2010; 149(6):282-4. PubMed ID: 20662475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study.
    Lin HC; Kachingwe BH; Lin HL; Cheng HW; Uang YS; Wang LH
    Pharmacotherapy; 2014 Jan; 34(1):36-45. PubMed ID: 23864581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin: risk-benefit profile with a focus on cancer.
    Provinciali N; Lazzeroni M; Cazzaniga M; Gorlero F; Dunn BK; DeCensi A
    Expert Opin Drug Saf; 2015 Oct; 14(10):1573-85. PubMed ID: 26359221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
    Ozawa H; Murai Y; Ozawa T
    Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-on therapies to metformin for type 2 diabetes.
    Shomali M
    Expert Opin Pharmacother; 2011 Jan; 12(1):47-62. PubMed ID: 21142694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006.
    Casscells SW; Granger E; Swedorske J; Goldhammer R; Shaheen M; Dorris J; Hong A; Wiktor M
    Am J Ther; 2008; 15(3):198-205. PubMed ID: 18496256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral antidiabetic drugs in 2003].
    Ducobu J
    Rev Med Brux; 2003 Sep; 24(4):A361-8. PubMed ID: 14606302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current and future aspects of oral antidiabetic agents in type 2 diabetes].
    Rybka J
    Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.